publication venue for
- Development of Methamphetamine Abuse-Deterrent Formulations Using Sucrose Acetate Isobutyrate.. 109:1338-1346. 2020
- Integrating QbD Tools for Flexible Scale-Up Batch Size Selection for Solid Dosage Forms.. 109:1223-1230. 2020
- Univariate and Multivariate Models for Determination of Prasugrel Base in the Formulation of Prasugrel Hydrochloride Using XRPD Method.. 108:3575-3581. 2019
- Development and Validation of a Discriminatory Dissolution Method for Rifaximin Products.. 108:2112-2118. 2019
- Quality and In-Use Stability Comparison of Brand and Generics of Extended-Release Phenytoin Sodium Capsules.. 108:1808-1817. 2019
- Chemometric Models for Quantification of Carbamazepine Anhydrous and Dihydrate Forms in the Formulation.. 108:1211-1219. 2019
- Sample Size for Tablet Compression and Capsule Filling Events During Process Validation.. 106:3533-3538. 2017
- Effect of Isopropyl Myristate on Transdermal Permeation of Testosterone From Carbopol Gel.. 106:1805-1813. 2017
- Evaluation of the In Vitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate.. 105:864-875. 2016
- Spectroscopic-Based Chemometric Models for Quantifying Low Levels of Solid-State Transitions in Extended Release Theophylline Formulations.. 105:97-105. 2016
- Evaluation of In-Use Stability of Anticoagulant Drug Products: Warfarin Sodium.. 104:4232-4240. 2015
- Chemometric Model Development and Comparison of Raman and (13)C Solid-State Nuclear Magnetic Resonance-Chemometric Methods for Quantification of Crystalline/Amorphous Warfarin Sodium Fraction in the Formulations.. 104:2550-2558. 2015
- Bioreactor process parameter screening utilizing a Plackett-Burman design for a model monoclonal antibody.. 104:1919-1928. 2015
- Comparison of X-ray powder diffraction and solid-state nuclear magnetic resonance in estimating crystalline fraction of tacrolimus in sustained-release amorphous solid dispersion and development of discriminating dissolution method.. 104:1777-1786. 2015
- Chemometric methods for the quantification of crystalline tacrolimus in solid dispersion by powder X-ray diffractrometry.. 103:2819-2828. 2014
- Near-infrared and fourier transform infrared chemometric methods for the quantification of crystalline tacrolimus from sustained-release amorphous solid dispersion.. 103:2376-2385. 2014
- An integrated process analytical technology (PAT) approach to monitoring the effect of supercooling on lyophilization product and process parameters of model monoclonal antibody formulations.. 103:2042-2052. 2014
- Stereomicroscopic imaging technique for the quantification of cold flow in drug-in-adhesive type of transdermal drug delivery systems.. 103:1433-1442. 2014
- United States Food and Drug Administration and Department of Defense shelf-life extension program of pharmaceutical products: progress and promise.. 103:1331-1336. 2014
- A study on Fe(2+) - α-helical-rich keratin complex formation using isothermal titration calorimetry and molecular dynamics simulation.. 103:1224-1232. 2014
- Analytical methods for the evaluation of melamine contamination.. 103:539-544. 2014
- Characterization of a nonribosomal peptide antibiotic solid dispersion formulation by process analytical technologies sensors.. 102:4337-4346. 2013
- Chemometric evaluation of near infrared, fourier transform infrared, and Raman spectroscopic models for the prediction of nimodipine polymorphs.. 102:4024-4035. 2013
- Development and evaluation of paclitaxel nanoparticles using a quality-by-design approach.. 102:3748-3761. 2013
- Oseltamivir phosphate-amberlite(TM) IRP 64 ionic complex for taste masking: preparation and chemometric evaluation.. 102:1800-1812. 2013
- Process analytical technology to understand the disintegration behavior of alendronate sodium tablets.. 102:1513-1523. 2013
- Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.. 102:1370-1381. 2013
- Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol.. 101:3753-3762. 2012
- Spontaneous carbonate formation in an amorphous, amine-rich, polymeric drug substance: sevelamer HCl product quality.. 101:2681-2685. 2012
- Chemometric evaluation of brompheniramine-tannate complexes.. 101:1450-1461. 2012
- Quality-by-design: an integrated process analytical technology approach to determine the nucleation and growth mechanisms during a dynamic pharmaceutical coprecipitation process.. 100:1969-1986. 2011
- Quality-by-Design (QbD): an integrated process analytical technology (PAT) approach for real-time monitoring and mapping the state of a pharmaceutical coprecipitation process.. 99:1516-1534. 2010
- Spectral and spatial characterization of protein loaded PLGA nanoparticles.. 99:1180-1192. 2010
- Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate.. 99:142-153. 2010
- Quality-by-design (QbD): an integrated approach for evaluation of powder blending process kinetics and determination of powder blending end-point.. 98:2784-2798. 2009
- Robust calibration design in the pharmaceutical quantitative measurements with near-infrared (NIR) spectroscopy: Avoiding the chemometric pitfalls.. 98:1155-1166. 2009
- Functionality of magnesium stearate derived from bovine and vegetable sources: dry granulated tablets.. 97:5328-5340. 2008
- Quality-by-design (QbD): effects of testing parameters and formulation variables on the segregation tendency of pharmaceutical powder measured by the ASTM D 6940-04 segregation tester.. 97:4485-4497. 2008
- Process analytical technology: nondestructive evaluation of cyclosporine A and phospholipid solid dispersions by near infrared spectroscopy and imaging.. 97:3388-3399. 2008
- Process analytical technology (PAT): quantification approaches in terahertz spectroscopy for pharmaceutical application.. 97:970-984. 2008
- Drug product characterization by macropixel analysis of chemical images.. 96:3390-3401. 2007
- Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells.. 96:2808-2817. 2007
- Quality by design: understanding the product variability of a self-nanoemulsified drug delivery system of cyclosporine A.. 96:2409-2423. 2007
- Process analytical technology: chemometric analysis of Raman and near infra-red spectroscopic data for predicting physical properties of extended release matrix tablets.. 96:1356-1365. 2007
- Cytotoxicity evaluation of enzyme inhibitors and absorption enhancers in Caco-2 cells for oral delivery of salmon calcitonin.. 93:1070-1082. 2004
- Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin.. 93:675-683. 2004
- Protection of salmon calcitonin breakdown with serine proteases by various ovomucoid species for oral drug delivery.. 93:392-406. 2004
- Preparation and characterization of a customized cellulose acetate butyrate dispersion for controlled drug delivery.. 91:1512-1522. 2002
- Design, in vitro stability, and ocular hypotensive activity of t-butalone chemical delivery systems.. 90:1026-1033. 2001
- Novel site-specific chemical delivery system as a potential mydriatic agent: formation of phenylephrine in the iris-ciliary body from phenylephrone chemical delivery systems.. 90:12-22. 2001
- Permeability characteristics of novel mydriatic agents using an in vitro cell culture model that utilizes SIRC rabbit corneal cells.. 88:180-184. 1999
- Racemate and enantiomers of ketoprofen: phase diagram, thermodynamic studies, skin permeability, and use of chiral permeation enhancers.. 87:833-840. 1998
- Effect of menthol and related terpenes on the percutaneous absorption of propranolol across excised hairless mouse skin.. 86:1369-1373. 1997
- In vitro evaluation of a controlled-release site-specific diisovaleryl tert-butalone chemical delivery system for the eye.. 83:450-453. 1994
- Physical characterization and dissolution properties of ibuprofen: Eudragit coprecipitates.. 80:799-804. 1991
- Effects of N-demethylated carbachol on iris and ciliary muscles.. 69:332-334. 1980
- Pharmacological studies on N-demethylated carbachol.. 67:531-535. 1978